Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2007

View Archived Issues

Phase I clinical study of DC/Apo-Nec melanoma vaccine

Newly formed Altair focuses on therapy for respiratory conditions

Cubist obtains option to acquire Illumigen

Omrix's fibrin patch demonstrates safety in phase I

Savient makes progress in phase III trial of Puricase for treatment-failure gout

DSMB recommends continuation of phase III Medidur trial

Dara BioSciences and Bayer sign metabolic disease alliance

Innocoll files IND for CollaRx bupivacaine topical

Novel anti-Helicobacter pylori agents imparted in recent aRigen patent

Agreement to develop Erbitux for mCRC in Japan

Phase I trial commences for Lu-AA-24493 in acute ischemic stroke

Ampakine molecules could be useful in treating Rett syndrome / News in Context

In vivo antitumor activity of meriolin-3, a novel CDK inhibitor

Careload receives marketing approval in Japan for PAH

New treatment options for inflammatory disorders disclosed in recent patents

Implicit awarded U.S. government contract for biodefense drug

Abbott and Solvay sign Simcor copromotion agreement in U.S.

Levemir approved in Japan for type 1 and 2 diabetes

Plavix sNDA approved to include acute coronary syndrome patients in Japan

Tarceva approved for lung cancer patients in Japan

Kissei Pharmaceutical receives approval in Japan for additional indication of Salagen

Mochida Pharmaceutical receives approval in Japan for Dinagest for endometriosis

Taxotere receives positive opinion in the E.U. for head and neck cancer

Recent patents describe novel antipsychotic agents

Voltaren gel receives U.S. regulatory approval for osteoarthritis pain

FDA issues approvable letter for telavancin in cSSSIs

Renvela receives FDA approval for dialysis patients

Escitalopram could be effective for the treatment of premature ejaculation / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...